Composition for resisting skin aging based on andrographolide

By combining andrographolide and recombinant human type XVII collagen in anti-skin aging products, the problem of UVB-induced epidermal stem cell damage in existing technologies has been solved, achieving more effective anti-aging and sensitivity improvement effects on the skin.

CN118986771AInactive Publication Date: 2024-11-22PROYA COSMETICS CO LTD

Patent Information

Application Number
CN202411483851.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-23
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is no existing record of andrographolide and recombinant human type XVII collagen effectively preventing UVB-induced epidermal stem cell damage, and no research has been reported on the combination of the two to combat UVB-induced epidermal stem cell damage.

Method used

Andrographolide is combined with recombinant human type XVII collagen at a specific mass ratio and applied to anti-skin aging products, including toners, serums, lotions, emulsions, creams, and masks. This synergistically combats UVB-induced epidermal stem cell damage by enhancing the proliferation and dryness of epidermal stem cells.

Benefits of technology

It achieved more effective resistance to skin aging and improvement of skin sensitivity, significantly improved the survival rate of epidermal stem cells, increased the expression levels of integrin β1 and p63, while reducing the expression of K10 and repairing UVB-induced epidermal stem cell damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986771A_ABST
    Figure CN118986771A_ABST
Patent Text Reader

Abstract

The invention discloses a composition for resisting skin aging based on andrographolide. The composition is prepared from andrographolide and recombinant human XVII type collagen. The combined use effect of the andrographolide and the recombinant human XVII type collagen is determined through research, and the andrographolide and the recombinant human XVII type collagen can synergistically resist UVB-induced epidermal stem cell injury by enhancing epidermal stem cell proliferation and dryness, so that skin aging is more effectively resisted, and meanwhile, the skin sensitive condition is improved and repaired.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of cosmetics, in particular to an andrographolide-based composition for resisting skin aging. Background Art

[0002] In the field of dermatology and regenerative medicine, epidermal stem cells (ESCs) have received extensive attention due to their key role in skin repair, regeneration and maintaining skin homeostasis. With the in-depth study of the aging mechanism, people have gradually realized that skin aging is not only manifested in wrinkles and sagging in appearance, but also involves complex changes at the cellular and molecular levels, especially the decline of epidermal stem cell function.

[0003] During the aging process of skin, the proliferation ability of epidermal stem cells decreases, resulting in a slowdown in skin regeneration. At the same time, the skin barrier function weakens, which reduces the skin's ability to resist the external environment and makes symptoms such as dryness and sensitivity more likely to occur.

[0004] Therefore, promoting the proliferation of epidermal stem cells and maintaining their function are key strategies to achieve anti-aging and sensitivity improvement of the skin. Among them, epidermal stem cell stemness markers (such as integrin β1 and p63) play an important role in regulating the behavior of epidermal stem cells and can maintain the self-renewal pluripotency of epidermal stem cells. In addition, although keratin 10 (K10) plays a role in skin differentiation and barrier function, reducing the expression of K10 may help regulate the terminal differentiation of epidermal cells, thereby slowing down the skin aging process.

[0005] As a natural plant active ingredient, Andrographis paniculata extract has been proven to have multiple biological activities such as anti-inflammatory, antioxidant and cell regeneration. As described in patent CN115414294A, Andrographis paniculata extract plays an important role in herbal soothing and repairing essence, helping to improve the environmental ecology of sensitive skin and repair damaged skin barriers. It has also been clarified that Andrographis paniculata extract can promote the proliferation of epidermal stem cells by upregulating integrin β1 expression and exert anti-aging effects. At the same time, as described in patent CN105358676B, andrographolide, the main active ingredient of Andrographis paniculata extract, can promote the proliferation of skin stem cells and skin cells, improve skin wrinkles and enhance skin regeneration ability.

[0006] Although andrographolide has multiple biological activities, there is no record that andrographolide can prevent UVB-induced epidermal stem cell damage.

[0007] On the other hand, as an important skin structural protein, type XVII collagen is a key component connecting the cytoskeleton and the basement membrane. It not only maintains skin integrity, but is also a key factor in regulating a variety of stem cells and is related to the aging phenotype. In the process of skin wound repair, type XVII collagen plays an important role by affecting the migration, proliferation and differentiation of stem cells. Patent CN113185604B provides a recombinant human type XVII collagen, which is efficiently expressed in Pichia pastoris and exhibits excellent cell adhesion activity and cell migration promotion activity.

[0008] However, there is currently no record that recombinant human type XVII collagen can protect epidermal stem cells from UVB-induced damage.

[0009] In summary, the prior art still has the following problems: 1. There is currently no record that andrographolide can prevent UVB-induced epidermal stem cell damage; 2. Currently, there is no record that recombinant human type XVII collagen can protect epidermal stem cell damage induced by UVB; 3. Currently, there is no record of combining andrographolide with recombinant human type XVII collagen to synergistically combat UVB-induced epidermal stem cell damage. Summary of the invention

[0010] The purpose of the present invention is to provide an anti-skin aging composition based on andrographolide, which has the effect of synergistically resisting UVB-induced epidermal stem cell damage.

[0011] The technical solution of the present invention is: an andrographolide-based anti-skin aging composition, comprising andrographolide and recombinant human type XVII collagen; the mass ratio of andrographolide to recombinant human type XVII collagen is 0.01:1-0.04:1.

[0012] In the aforementioned andrographolide-based anti-skin aging composition, the mass ratio of andrographolide to recombinant human type XVII collagen is 0.019:1.

[0013] In the aforementioned andrographolide-based anti-skin aging composition, the mass ratio of andrographolide to recombinant human type XVII collagen is 0.038:1.

[0014] The aforementioned andrographolide-based anti-skin aging composition is applied to products for anti-skin aging and improving skin sensitivity; the products at least include lotion, essence, lotion, emulsion, cream and facial mask.

[0015] In the aforementioned andrographolide-based anti-skin aging composition, the mass proportion of the composition in the product is 0.1%-2%.

[0016] Compared with the prior art, the present invention has determined the efficacy of the combined use of andrographolide and recombinant human type XVII collagen, which can synergistically combat UVB-induced epidermal stem cell damage by enhancing the proliferation and stemness of epidermal stem cells, thereby more effectively resisting skin aging and improving and repairing skin sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 is the UVB damage condition of epidermal stem cells in the embodiment of the present invention; Figure 2 The effects of andrographolide and recombinant human type XVII collagen on UVB-damaged epidermal stem cells in the examples of the present invention, where "*", "#", "&", and "%" represent significance, *** p <0.001,** p <0.01, ### p <0.001, &&& p <0.001, && p <0.01, % p <0.05; Figure 3 The effect of andrographolide and recombinant human type XVII collagen on the expression of integrin β1 in UVB-damaged epidermal stem cells in the examples of the present invention, where “*” and “#” represent significance, * p <0.05, ### p <0.001; Figure 4 The effect of andrographolide and recombinant human type XVII collagen on the expression of p63 in UVB-damaged epidermal stem cells in the present invention. "*" and "#" represent significant differences. * p <0.05, ### p <0.001; Figure 5 The effects of andrographolide and recombinant human type XVII collagen on K10 expression in UVB-damaged epidermal stem cells in the examples of the present invention, where “*”, “#” and “&” represent significance, * p <0.05, ## p <0.01, & p <0.05. DETAILED DESCRIPTION

[0018] The present invention is further described below in conjunction with the accompanying drawings and embodiments, but they are not intended to limit the present invention.

[0019] Example 1. An andrographolide-based anti-skin aging composition comprises andrographolide and recombinant human type XVII collagen; the mass ratio of andrographolide to recombinant human type XVII collagen is 0.01:1-0.04:1.

[0020] The composition is applied to products for resisting skin aging and improving skin sensitivity; the products at least include lotion, essence, lotion, emulsion, cream and mask.

[0021] The mass proportion of the composition in the product is 0.1%-2%.

[0022] Example 2. An anti-skin aging composition based on andrographolide, wherein the mass ratio of andrographolide to recombinant human type XVII collagen is 0.019:1.

[0023] Example 3. An anti-skin aging composition based on andrographolide, wherein the mass ratio of andrographolide to recombinant human type XVII collagen is 0.038:1.

[0024] Experimental comparison and verification Composition 1 (Example 2): the mass ratio of andrographolide to recombinant human type XVII collagen is 0.019:1; Composition 2 (Example 3): the mass ratio of andrographolide to recombinant human type XVII collagen is 0.038:1; AG group 1: andrographolide concentration was 0.038 μg / mL; AG group 2: andrographolide concentration was 0.076 μg / mL; COL 17: The concentration of recombinant human type XVII collagen is 2 μg / mL.

[0025] 1. Experimental Materials and Reagents AG (andrographolide, Shanghai Yuanye Biotechnology Co., Ltd., S24818); COL 17 (recombinant human type XVII collagen, Jiangsu Chuangjian Medical Technology Co., Ltd.); ESCs (epidermal stem cells, isolated from newborn SD rats); K-SFM medium, dispase II and 0.25% trypsin-EDTA (LifeTechnologies); integrin β1 antibody (BDbiosciences, 610468); recombinant p63 antibody (Abcam, SC-374057), recombinant K10 antibody (recombinant keratin 10 antibody, Abcam, ab76318).

[0026] 2. Sample preparation 1. Preparation of COL 17 Solution For water-soluble raw materials, weigh 0.04 g COL 17 and dissolve it in 1 mL phosphate buffer solution (PBS) in a centrifuge tube. After shaking and mixing until completely dissolved, use it as the mother liquor, filter and sterilize it, and dilute it with K-SFM medium according to different experimental concentrations.

[0027] 2. Preparation of Andrographolide (AG) Solution For oil-soluble raw materials, weigh 0.025 g AG and dissolve it in 1 mL DMSO. After shaking and mixing until completely dissolved, use it as the mother solution. Dilute it with K-SFM culture medium according to different experimental concentrations. The DMSO in the diluted solution should be ≤0.1%.

[0028] 3. Preparation of the composite (AG+COL 17) solution AG and COL 17 were mixed at different mass ratios (0.019:1, 0.038:1) and diluted using K-SFM medium.

[0029] 3. Experimental Methods 1. Determination of UVB modeling conditions for epidermal stem cells Epidermal stem cells (ESCs) were cultured at 1×10 4 Each well was inoculated in a 96-well plate. When the ESC cell density in the 96-well plate reached about 80%, UVB (150, 300, 450, 600 mJ / cm 2 ) The cells were irradiated and continued to be cultured in a 37°C, 5% CO2 incubator for 24 h after irradiation. The cell viability was assessed using the CCK-8 assay. 10 μL CCK-8 was added to each well and incubated in a 37°C, 5% CO2 incubator for 1-2 h. The absorbance was measured at 450 nm to calculate the survival rate of epidermal stem cells.

[0030] 2. Effect of samples on the survival rate of UVB-damaged epidermal stem cells ESCs were cultured at 1 × 10 4 Each well was inoculated in a 96-well plate. When the cell density in the 96-well plate reached about 80%, 100 μL of culture medium containing different concentrations of AG, COL 17 or a combination (AG+COL17) was added to each well. Then, UVB (450 mJ / cm 2 ) The cells were irradiated and then cultured in a 37 ℃, 5% CO2 incubator for 24 h. Cell viability was assessed using the CCK-8 assay.

[0031] 3. Effects of samples on UVB-induced damage to epidermal stem cells After 24 h of UVB irradiation, cells treated with AG, COL 17 or the combination (AG+COL 17) were lysed and protein was extracted, quantified by BCA, separated by 10% SDS-polyacrylamide gel, and transferred to a PVDF membrane; the membrane was blocked in 5% skim milk for 2 h, cut and incubated with integrin β1 antibody, recombinant p63 antibody and recombinant K10 antibody, respectively, and then incubated with HRP-conjugated secondary antibody (goat anti-mouse or rabbit); after each incubation, the membrane was washed with TBST to remove unbound antibodies; the bands treated with ECL reagent were visualized by a Bio-Rad chemiluminometer, and the data were quantitatively analyzed by Image Lab software.

[0032] Statistical Analysis All values ​​are expressed as mean ± SD (n = 6); the significance of the difference between the two groups was determined using t-test; p value < 0.05 was considered statistically significant.

[0033] V. Results Analysis 1. Determination of UVB modeling conditions for epidermal stem cells Table 1 Exploration of UVB damage conditions for epidermal stem cells

[0034] like Figure 1 The ESCs injury model was established by UVB irradiation. UVB irradiation significantly reduced the activity of ESCs. When the UVB irradiation dose was 450 mJ / cm 2 The survival rate of ESCs was 60.99%, so this irradiation intensity was subsequently selected to induce damage to epidermal stem cells.

[0035] 2. Effect of samples on the survival rate of epidermal stem cells Table 2 Effects of andrographolide and recombinant human type XVII collagen on UVB-damaged epidermal stem cells

[0036] like Figure 2 , the ESCs injury model was established by UVB irradiation, and the cells were treated with AG, COL 17, and the combination (AG+COL 17); Compared with the model group, different concentrations of AG can effectively improve the survival rate of ESCs damaged by UVB, showing a significant cell protection effect; when AG and COL 17 were used in combination at a mass ratio of 0.019:1, that is, 0.038 μg / mL AG and 2 μg / mL COL 17 were mixed, the survival rate of ESCs damaged by UVB was significantly improved compared with the use of 2 μg / mL COL 17 alone (p < 0.05); The combined effect of AG and COL 17 was evaluated according to the Bliss independence method, and the CI was calculated to be <1, which indicated that the combined use of 0.038 μg / mL AG and 2 μg / mL COL 17 had a synergistic effect and could more effectively improve the survival rate of UVB-damaged ESCs.

[0037] When AG and COL 17 were used in combination at a mass ratio of 0.038:1, that is, 0.076 μg / mL AG and 2 μg / mL COL 17, the survival rate of UVB-damaged ESCs was significantly improved compared with the use of 0.076 μg / mL AG or 2 μg / mL COL 17 alone (p < 0.001). The combined effect of AG and COL 17 was evaluated according to the Bliss independence method, and the CI was calculated to be <1, which indicated that the combined use of 0.076 μg / mL AG and 2 μg / mL COL 17 had a synergistic effect and could more effectively improve the survival rate of UVB-damaged ESCs.

[0038] At the same time, compared with the efficacy of the combination with a mass ratio of AG to COL 17 of 0.019:1, the cell protection effect presented by the mass ratio of AG to COL 17 of 0.038:1 was more significant (p < 0.01).

[0039] According to the results of the cell survival rate experiment, we selected a composition with a mass ratio of AG to COL 17 of 0.038:1 (composition 2) for subsequent research on epidermal stem cell stemness indicators.

[0040] 3. Effect of samples on the stemness of epidermal stem cells The ESCs injury model was established by UVB irradiation, and the cells were treated with AG, COL17, and the combination (AG+COL 17). After UVB treatment, the expression levels of integrin β1 and p63 in ESCs were significantly reduced, while the expression level of K10 was significantly increased. These changes indicate that UVB radiation damages ESCs, resulting in reduced cell adhesion and stem cell properties, while increased keratinization may accelerate epidermal stem cell differentiation.

[0041] Table 3 Effects of andrographolide and recombinant human type XVII collagen on integrin β1 expression in UVB-damaged epidermal stem cells

[0042] like Figure 3 Compared with the blank control, the expression level of integrin β1 in ESCs was significantly decreased after UVB treatment (p < 0.001). When AG and COL 17 were used in combination at a mass ratio of 0.038:1, that is, 0.076 μg / mL AG and 2 μg / mL COL 17, the expression level of integrin β1 in UVB-damaged ESCs was significantly increased compared with the model group (p < 0.05).

[0043] The effect of combined use of AG and COL 17 on the expression level of integrin β1 was evaluated according to the Bliss independence method, and the calculated CI was <1, which indicated that the combined use of AG and COL 17 had a synergistic effect and could more effectively increase the expression level of integrin β1 in UVB-damaged ESCs.

[0044] Table 4 Effects of andrographolide and recombinant human type XVII collagen on p63 expression in UVB-damaged epidermal stem cells

[0045] like Figure 4 Compared with the blank control, the expression level of p63 in ESCs was significantly decreased after UVB treatment (p < 0.001). When AG and COL 17 were used in combination at a mass ratio of 0.038:1, that is, 0.076 μg / mL AG and 2 μg / mL COL 17, the expression level of p63 in UVB-damaged ESCs was significantly increased compared with the model group (p < 0.05).

[0046] The effect of combined use of AG and COL 17 on the expression level of p63 was evaluated according to the Bliss independence method, and the calculated CI was <1, which indicated that the combined use of AG and COL 17 had a synergistic effect and could more effectively increase the expression level of p63 in UVB-damaged ESCs.

[0047] Table 5 Effects of andrographolide and recombinant human type XVII collagen on K10 expression in UVB-damaged epidermal stem cells

[0048] like Figure 5Compared with the blank control, the expression level of K10 in ESCs was significantly increased after UVB treatment (p < 0.01). When AG and COL 17 were used in combination at a mass ratio of 0.038:1, that is, 0.076 μg / mL AG and 2 μg / mL COL17, the expression level of K10 in UVB-damaged ESCs was significantly reduced compared with the model group (p < 0.05).

[0049] The effect of combined use of AG and COL 17 on the expression level of K10 was evaluated according to the Bliss independence method, and the calculated CI was <1, which indicated that the combined use of AG and COL 17 had a synergistic effect and could more effectively reduce the expression level of K10 in UVB-damaged ESCs.

[0050] Drug combination therapy is a long-standing and widely used strategy in modern medicine that improves efficacy, reduces toxicity, and reduces the development of drug resistance by exploiting the synergistic effects of multiple active ingredients. This treatment approach has become standard in the treatment of diseases such as cancer, hypertension, asthma, and AIDS, and is gradually showing great potential in the field of dermatology. In the process of rational development of drug combinations, many theoretical and experimental articles have been published to evaluate the methodological approach to the efficacy evaluation of combined medications.

[0051] Among them, the Bliss Independence model is widely used in pharmacological research to evaluate the interaction of drug combinations, especially in the preliminary screening and evaluation of potential drug combinations. It is a statistical method for evaluating the effects of two or more drug combinations. The effect of drug combinations can be evaluated by calculating the Combination Index (CI), and the formula is:

[0052] E AB is the effect of the combination of drugs A and B; E A is the effect of drug A alone; E B is the effect of drug B alone.

[0053] If CI < 1, the drug combination is considered to exhibit synergistic effects.

[0054] If CI = 1, the drug combination is considered to exhibit an additive effect.

[0055] If CI>1, the drug combination is considered to exhibit antagonism.

Claims

1. An anti-skin aging composition based on andrographolide, characterized in that: The invention comprises andrographolide and recombinant human type XVII collagen; the mass ratio of andrographolide to recombinant human type XVII collagen is 0.01:1-0.04:

1.

2. The anti-skin aging composition based on andrographolide according to claim 1, characterized in that: The mass ratio of andrographolide to recombinant human type XVII collagen is 0.019:

1.

3. The anti-skin aging composition based on andrographolide according to claim 1, characterized in that: The mass ratio of andrographolide to recombinant human type XVII collagen is 0.038:

1.

4. The anti-skin aging composition based on andrographolide according to any one of claims 1 to 3, characterized in that: The composition is applied to products for resisting skin aging and improving skin sensitivity; the products at least include lotion, essence, lotion, emulsion, cream and mask.

5. The anti-skin aging composition based on andrographolide according to claim 4, characterized in that: The mass proportion of the composition in the product is 0.1%-2%.

Citation Information

Patent Citations

  • Synthetic products for improving skin condition containing andrographis paniculata extract or andrographolide or its salts

    CN105358676B

  • A recombinant human type XVII collagen, its preparation method and application

    CN113185604B

  • Herbal soothing and repairing essence and preparation method thereof

    CN115414294A

  • Composition for improving skin condition, comprising extract of andrographis paniculata, andrographolide or salt thereof

    CN105358676A

  • Application of collagen composition in preparation of anti-aging product and external cosmetic containing collagen composition

    CN115154356A

Cited By

  • A composition for regulating the biomechanical homeostasis of the skin basement membrane and its use

    CN122973295A